In the BioHarmony Drug Report Database

"Preview" Icon

Secukinumab

Cosentyx (secukinumab) is an antibody pharmaceutical. Secukinumab was first approved as Cosentyx on 2015-01-14. It is used to treat ankylosing spondylitis and psoriatic arthritis in the USA. It has been approved in Europe to treat ankylosing spondylitis, psoriasis, and psoriatic arthritis. The pharmaceutical is active against interleukin-17A.

 

Trade Name

 

Cosentyx
 

Common Name

 

secukinumab
 

ChEMBL ID

 

CHEMBL1743068
 

Indication

 

ankylosing spondylitis, psoriasis, psoriatic arthritis
 

Drug Class

 

Monoclonal antibodies: interleukins as targets|monoclonal antibodies: fully human, neural indications

Image (chem structure or protein)

Secukinumab structure rendering